Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Operating Expenses (2024 - 2025)

Historic Other Operating Expenses for ARS Pharmaceuticals (SPRY) over the last 2 years, with Q3 2025 value amounting to $8.2 million.

  • ARS Pharmaceuticals' Other Operating Expenses rose 721339.29% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year increase of 1341250.0%. This contributed to the annual value of $977000.0 for FY2024, which is N/A changed from last year.
  • ARS Pharmaceuticals' Other Operating Expenses amounted to $8.2 million in Q3 2025, which was up 721339.29% from $5.0 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Other Operating Expenses peaked at $8.2 million during Q3 2025, and registered a low of $112000.0 during Q3 2024.